Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 322Magnetic Resonance Spectroscopy 219Biopsy 186Nivolumab 50X-Rays 45Radiation 42Immunoglobulin G 42Disulfides 42Paclitaxel 40Cyclophosphamide 40pembrolizumab 39Taxes 39Cisplatin 39Platinum 371,2-diaminocyclohexaneplatinum II citrate 37Carboplatin 36Radiotherapy 33atezolizumab 30Doxorubicin 30olaparib 25Gemcitabine 25venetoclax 24Ipilimumab 24CTLA-4 Antigen 24Bevacizumab 24Prednisone 22Vincristine 21Phantoms, Imaging 21cabozantinib 20durvalumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × pevonedistat × 30 days × Clear all
NCT04175912 2026-05-29

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡